Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $100 and keeps an Outperform rating on the shares. The firm believes the FDA approval of Icotyde for psoriasis had been widely expected due to compelling Phase 3 data, and is raising its price target following model adjustments based on what Wedbush sees as a favorable label. The firm sees additional upside in Protagonist Therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
- Protagonist Therapeutics price target raised to $125 from $115 at Citi
- Protagonist Therapeutics price target raised to $119 from $113 at Barclays
- Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
- Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target